Hu, Lili and van der Sluis, Renee M. and Castelino, Kennith Brian and Zhang, Bao-Cun and Ronit, Andreas and Zillinger, Thomas and Werner, Marvin and Jørgensen, Sofie Eg and Hansen, Anne Louise and Pedersen, Alice and Narita, Ryo and Reinert, Line S. and Bundgaard, Bettina and Abel, Laurent and Aiuti, Alessandro and Al-Muhsen, Saleh and Al-Mulla, Fahd and Anderson, Mark S. and Andreakos, Evangelos and Arias, Andrés A. and Arkin, Lisa M. and Feldman, Hagit Baris and Bastard, Paul and Belot, Alexandre and Biggs, Catherine M. and Bogunovic, Dusan and Bolze, Alexandre and Bondarenko, Anastasiia and Borghesi, Alessandro and Bousfiha, Ahmed A. and Brodin, Petter and Bryceson, Yenan and Casari, Giorgio and Christodoulou, John and Cobat, Aurélie and Colobran, Roger and Condino-Neto, Antonio and Constantinescu, Stefan N. and Cooper, Megan A. and Dalgard, Clifton L. and Desai, Murkesh and Drolet, Beth A. and Dündar, Munis and Duval, Xavier and Duvlis, Sotirija and El Baghdadi, Jamila and Eloy, Philippine and Espinosa-Padilla, Sara and Fellay, Jacques and Flores, Carlos and Franco, José Luis and Froidure, Antoine and Gorochov, Guy and Gut, Marta and Haerynck, Filomeen and Hagin, David and Halwani, Rabih and Hammarström, Lennart and Heath, James R. and Hsieh, Elena W. Y. and Husebye, Eystein and Imai, Kohsuke and Itan, Yuval and Jouanguy, Emmanuelle and Kaja, Elżbieta and Karamitros, Timokratis and Kisand, Kai and Ku, Cheng-Lung and Lau, Yu-Lung and Ling, Yun and Lucas, Carrie L. and Mahévas, Matthieu and Mansouri, Davood and Maródi, László and Mentré, France and Meyts, Isabelle and Milner, Joshua D. and Mironska, Kristina and Morio, Tomohiro and Ng, Lisa F. P. and Notarangelo, Luigi D. and Novelli, Antonio and Novelli, Giuseppe and O’Farrelly, Cliona and Okada, Satoshi and Okamoto, Keisuke and Ozcelik, Tayfun and Ozcelik, Firat and Pan-Hammarström, Qiang and de Diego, Rebeca Perez and Perez-Tur, Jordi and Perlin, David S. and Peter, Jonny and Planas, Anna M. and Prando, Carolina and Pujol, Aurora and Puel, Anne and Quintana-Murci, Lluis and Ramaswamy, Sathishkumar and Renia, Laurent and Resnick, Igor and Rodríguez-Gallego, Carlos and Sancho-Shimizu, Vanessa and Sediva, Anna and Seppänen, Mikko R. J. and Shahrooei, Mohammad and Shcherbina, Anna and Slaby, Ondrej and Snow, Andrew L. and Soler-Palacín, Pere and Soumelis, Vassili and Spaan, András N. and Su, Helen C. and Tancevski, Ivan and Tangye, Stuart G. and Tayoun, Ahmad Abou and Temel, Şehime Gülsün and Thorball, Christian and Tiberghien, Pierre and Trouillet-Assant, Sophie and Turvey, Stuart E. and Uddin, K. M. Furkan and Uddin, Mohammed J. and van de Beek, Diederik and Vianna, Fernanda Sales Luiz and Vinh, Donald C. and von Bernuth, Horst and Wauters, Joost and Zatz, Mayana and Zhang, Qian and Zhang, Shen-Ying and Bodilsen, Jacob and Hansen, Kristoffer Skaalum and Storgaard, Merete and Benfield, Thomas and Helleberg, Marie and Holm, Christian K. and Cobat, Aurelie and Casanova, Jean-Laurent and Reggiori, Fulvio and Mari, Muriel and Paludan, Søren R. and Mogensen, Trine H. (2025) Deleterious variants in the autophagy-related gene RB1CC1/FIP200 impair immunity to SARS-CoV-2. Nature Communications, 16 (1). ISSN 2041-1723
![[thumbnail of 2025 article.pdf]](https://eprints.ugd.edu.mk/style/images/fileicons/text.png "2025 article.pdf")
Text
2025 article.pdf
Download (7MB)
Abstract
The clinical outcome of SARS-CoV-2 infection spans from asymptomatic viral elimination to lethal COVID-19 pneumonia, which is due to type I interferon (IFN) deficiency in at least 15-20% of cases. We report two unrelated male patients with critical COVID-19 who are heterozygous for rare deleterious variants in RB1CC1, encoding the autophagy-related FIP200 protein. Airway epithelial cells genetically deprived of FIP200 or cell lines expressing the RB1CC1/FIP200 patient variants exhibit elevated SARS-CoV-2 replication and impaired autophagic flux. The antiviral function of FIP200 is independent of canonical autophagy and type I IFN, but involves the selective autophagy receptor NDP52. We identify a non-canonical function of FIP200 in a novel lysosomal degradation pathway, in which SARS-CoV-2 virions are targeted to single-membrane compartments for degradation of viral RNA in LC3B-positive acidified vesicles. This pathway is impaired in FIP200-deficient cells and in cells expressing FIP200 patient haplotypes. Collectively, we describe a cell-autonomous anti-SARS-CoV-2 restriction pathway, dependent on FIP200 and NDP52, and independent of canonical autophagy and type I IFN, which can underlie critical COVID-19 pneumonia.
| Item Type: | Article |
|---|---|
| Subjects: | Medical and Health Sciences > Basic medicine Medical and Health Sciences > Health sciences |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Sotirija Duvlis |
| Date Deposited: | 05 Feb 2026 08:18 |
| Last Modified: | 05 Feb 2026 08:18 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/37796 |
Actions (login required)
- View Item